

Karl Mullen

Associate, New York



PHONE: 212-808-2910
kmullen@desmaraisllp.com

FAX: 212-351-3401

Karl Mullen's practice focuses on patent infringement litigation in the electronics and life sciences industries (including ANDA litigation). He has experience in all phases of patent litigation up through trial preparations, including motion practice, taking depositions, and working with and preparing expert witnesses. Mr. Mullen has also assisted in proceedings before the Patent Trial and Appeal Board (PTAB), including assisting with drafting *inter partes* review petitions.

Mr. Mullen has represented multiple leading technology and life sciences companies. For example, Mr. Mullen was a part of a team that took over a patent infringement case against Cisco Systems, Inc. days before the close of discovery and months before trial. Within months of taking over the case, the team obtained a pre-trial finding of non-infringement as to all asserted claims. That finding of non-infringement was upheld on appeal to the Federal Circuit.

Before joining Desmarais LLP, Mr. Mullen worked for several research laboratories, including several focused on developing an HIV vaccine. During his time at the lab bench, Mr. Mullen's work was published five times across four separate labs. During law school, Mr. Mullen was a Web Editor for the Journal of Intellectual Property & Entertainment Law.

Prior Experience

- Summer Associate, Desmarais LLP, 2015

Memberships and Affiliations

- New York City Bar Association

Representative Matters

- Represented Cisco Systems, Inc. against Straight Path IP Group, LLC, in a patent infringement case. Our team obtained a finding of non-infringement as to all asserted claims.
- Represented a leading consumer electronics company against

EDUCATION

New York University School of Law, *cum laude*, J.D., 2016, Journal of Intellectual Property and Entertainment Law, Staff Editor; Intellectual Property and Entertainment Law Society

University of Michigan, B.S., Cellular and Molecular Biology, 2004

ADMISSIONS

2018, New York

allegations of patent infringement. The matter settled favorably ahead of trial.

- Represented IBM against allegations of patent infringement by Groupon, Inc. Helped develop petitions for *inter partes* review of Groupon's asserted patents. The matter settled favorably after another DLLP team obtained a finding of infringement against Groupon, Inc. in another matter.
- Represented a leading branded pharmaceutical company in an ANDA litigation. The matter settled favorably.
- Represented DoubleDown Interactive, LLC, against allegations of patent infringement by CG Technology Development, LLC, and others. Our team obtained multiple favorable rulings, contributing to a favorable settlement.

Publications

- Park, H., Adamson, L., Ha, T., **Mullen, K.**, Hagen, S. I., Nogueron, A., Sylwester, A. W., Axthelm, M. K., Legasse, A., Piatak, M., Jr, Lifson, J. D., McElrath, J. M., Picker, L. J., & Seder, R. A. (2013). Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV Gag protein-induced T cell responses in nonhuman primates. *Journal of Immunology*, 190(8), 4103–4115. [Read Publication](#)
- Yu, S., Satoh, A., Pypaert, M., **Mullen, K.**, Hay, J. C., & Ferro-Novick, S. (2006). mBet3p is required for homotypic COPII vesicle tethering in mammalian cells. *The Journal of Cell Biology*, 174(3), 359–368. [Read Publication](#)
- Geng, H., Zhu, Y., **Mullen, K.**, Zuber, C. S., & Nakano, M. M. (2007). Characterization of ResDE-dependent fnr transcription in *Bacillus subtilis*. *Journal of Bacteriology*, 189(5), 1745–1755. [Read Publication](#)
- Winstone, N., Wilson, A. J., Morrow, G., Boggiano, C., Chiuchiolo, M. J., Lopez, M., Kemelman, M., Ginsberg, A. A., **Mullen, K.**, Coleman, J. W., Wu, C. D., Narpala, S., Ouellette, I., Dean, H. J., Lin, F., Sardesai, N. Y., Cassamasa, H., McBride, D., Felber, B. K., Pavlakis, G. N., ... McDermott, A. B. (2011). Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. *Journal of Virology*, 85(18), 9578–9587. [Read Publication](#)
- Bentley, M., Liang, Y., **Mullen, K.**, Xu, D., Sztul, E., Hay, J. C. (2006). SNARE status regulates tether recruitment and function in homotypic COPII vesicle fusion. *The Journal of Biological Chemistry*, 281(50), 38825-33. [Read Publication](#)